Table of Content

1 Market Guides

  • 1.1 Immunoassay Market - Strategic Situation Analysis & COVID Impact
  • 1.2 Guide for Executives, Marketing, Sales and Business Development Staff
  • 1.3 Guide for Management Consultants and Investment Advisors

2 Introduction and Market Definition

  • 2.1 Immunoassay Markets Definition In This Report
    • 2.1.1 Enzyme Based
    • 2.1.2 Immunofluorescence
    • 2.1.3 Chemiluminescence
    • 2.1.4 DNA/NAT
    • 2.1.5 RIA & Other
    • 2.1.6 Reagents/Kits, Analyzers, Software & Services
    • 2.1.7 Infectious Disease
    • 2.1.8 Auto Immune
    • 2.1.9 Endocrinology
    • 2.1.10 Oncology
    • 2.1.11 Cardiology
    • 2.1.12 Other Specialty
  • 2.2 Market Definition
    • 2.2.1 Market Sizes
    • 2.2.2 Currency
    • 2.2.3 Years
  • 2.3 Methodology
    • 2.3.1 Authors
    • 2.3.2 Sources
  • 2.4 Perspective: Healthcare, the IVD Industry, and the COVID-19 Pandemic
    • 2.4.1 Global Healthcare Spending
    • 2.4.2 Spending on Diagnostics
    • 2.4.3 Important Role of Insurance for Diagnostics

3 Industry Overview

  • 3.1 Industry Participants
    • 3.1.1 IVD Supplier
    • 3.1.2 Independent lab specialized/esoteric
    • 3.1.3 Independent lab national/regional
    • 3.1.4 Independent lab analytical
    • 3.1.5 Public National/regional lab
    • 3.1.6 Hospital lab
    • 3.1.7 Physician lab
    • 3.1.8 Audit body
  • 3.2 The Clinical Laboratory Market Segments
    • 3.2.1 Traditional Market Segmentation
    • 3.2.2 Laboratory Focus and Segmentation
    • 3.2.3 Hospital Testing Share
    • 3.2.4 Economies of Scale
    • 3.2.5 Hospital vs. Central Lab
    • 3.2.6 Physician Office Lab's
    • 3.2.7 Physician's and POCT
  • 3.3 Immunoassay - Markets and Discussion
    • 3.3.1 Instruments - Genetics changes the picture
      • 3.3.1.1 RIA - A Technology Shows its Age
      • 3.3.1.2 Immunoassay vs. PCR vs. Sequencing - A See Saw Battle
      • 3.3.1.3 The Smart Shrinking Instrument - Serious Implications
      • 3.3.1.4 Research Funding and Capital Expense - Instrument Pooling
      • 3.3.1.5 Multiplex vs. POC - A Tradeoff Analysis
    • 3.3.2 Reagents and Kits - Genetics changes the picture
      • 3.3.2.1 Bigger Test Menus a Boon for Kit Market
      • 3.3.2.2 Physician Office Labs - A New Frontier
    • 3.3.3 Rapid and POCT to Threaten Instrument Markets
    • 3.3.4 OTC and DTC - Huge Market Potential
    • 3.3.5 Economies of Scale. Going Away?
    • 3.3.6 Lower Barriers to Entry for Instruments/Analyzers
    • 3.3.7 Miniturization and Technology Drive Acquisition

4 Market Trends

  • 4.1 Factors Driving Growth
    • 4.1.1 Diagnostic Factors
    • 4.1.2 Changing Technologies Spur Early Instrument Retirement
    • 4.1.3 Consumer Channels Open Wider
    • 4.1.4 Immunity Technology Comes of Age
  • 4.2 Factors Limiting Growth
    • 4.2.1 Increased Competition Lowers Price
    • 4.2.2 Threat from PCR Based Instruments
    • 4.2.3 Lower Barriers to Entry
    • 4.2.4 Wellness has a downside
  • 4.3 Immunoassay Instrumentation
    • 4.3.1 Instrumentation Tenacity
    • 4.3.2 Declining Cost of Instruments Changes Industry Structure
    • 4.3.3 LISTING of INSTRUMENT SPECIFICATIONS
    • 4.3.4 Immunoassay - CRISPR Diagnostics

5 Immunoassay Recent Developments

  • 5.1 Recent Developments - Importance and How to Use This Section
    • 5.1.1 Importance of These Developments
    • 5.1.2 How to Use This Section
  • 5.2 FDA Grants EUA to Xtrava Health COVID Point-of-Care Antigen Test
  • 5.3 Alamar Biosciences Raises $80M for Immuno-Sandwich Assay Platform
  • 5.4 FDA grants breakthrough device to multiplex immunoassay
  • 5.5 Quidel, Beckman Settle Cardiac Immunoassay Dispute
  • 5.6 BGI Americas, Advaite Form SARS-CoV-2 Testing Partnership
  • 5.7 BioMérieux Gets CE Mark for Three Dengue Immunoassays
  • 5.8 COVID-19 Portfolio to Accelerate At-Home Infectious Disease Testing
  • 5.9 Roche Diagnostics Expanding Testing Portfolio in 2021
  • 5.10 PerkinElmer Long-Term Outlook
  • 5.11 Quidel Updates Outlook for C19 Testing
  • 5.12 Dx Companies Look at Multiplex Tests for SARS-CoV-2, Influenza
  • 5.13 Becton Dickinson and NAT Diagnostics Acquisition
  • 5.14 New test diagnoses Lyme disease within 15 minutes
  • 5.15 Multiplexed Immunoassay System Differentiates Malaria Species
  • 5.16 ERBA Mannheim Unveils Next-Generation Nexus unit
  • 5.17 Uman Diagnostics And Bio-Techne Announce Agreement For Neurofilament Light Assay
  • 5.18 Software reduces variability in ELISA biomarker tests
  • 5.19 Arrayit Corporation Allergy Testing Network Doubles

6 Profiles of Key Companies

  • 6.1 Abbott Diagnostics
  • 6.2 Abcam
  • 6.3 Arlington Scientific
  • 6.4 Arrayit Corporation
  • 6.5 Autobio Diagnostics
  • 6.6 Awareness Technology
  • 6.7 Beckman Coulter Diagnostics
  • 6.8 Becton, Dickinson and Company
  • 6.9 Biocartis
  • 6.10 Biomatik
  • 6.11 bioMérieux Diagnostics
  • 6.12 Bioneer Corporation
  • 6.13 Bio-Rad Laboratories, Inc.
  • 6.14 BioTek Instruments
  • 6.15 Boditech Med, Inc
  • 6.16 Boster Biological Technology
  • 6.17 Diamedix (Erba Diagnostics)
  • 6.18 Diasorin S.p.A.
  • 6.19 Dynex Technologies
  • 6.20 Enzo Biochem
  • 6.21 Eurofins Scientific
  • 6.22 FUJIFILM Wako Diagnostics
  • 6.23 Fujirebio
  • 6.24 Gold Standard Diagnostics
  • 6.25 Grifols
  • 6.26 Hycor Biomedical
  • 6.27 Immunodiagnostic Systems (IDS)
  • 6.28 Immunodiagnostik AG
  • 6.29 Inova Diagnostics
  • 6.30 JR Biomedical
  • 6.31 Luminex Corp
  • 6.32 Maxim Biomedical
  • 6.33 Mbio Diagnostics
  • 6.34 Meso Scale Discovery
  • 6.35 Millipore Sigma
  • 6.36 Mindray
  • 6.37 Molecular Devices
  • 6.38 MP Biomedical
  • 6.39 MyCartis
  • 6.40 Operon
  • 6.41 Ortho Clinical Diagnostics
  • 6.42 Perkin Elmer
  • 6.43 Qiagen Gmbh
  • 6.44 Quidel
  • 6.45 R&D Systems
  • 6.46 Randox Toxicology
  • 6.47 Roche Molecular Diagnostics
  • 6.48 SD Biosensor
  • 6.49 Serametrix
  • 6.50 Siemens Healthineers
  • 6.51 Sysmex
  • 6.52 Tecan
  • 6.53 Thermo Fisher Scientific Inc.
  • 6.54 TOSOH Bioscience
  • 6.55 Veredus Laboratories
  • 6.56 Vircell
  • 6.57 YD Diagnostics
  • 6.58 Zhejiang Orient Gene Biotech

7 The Global Market

  • 7.1 Global Market by Country
    • 7.1.1 Global Market by Country Table
    • 7.1.2 Global Market by Country Chart
  • 7.2 Global Market by Application
    • 7.2.1 Global Market by Application Table
    • 7.2.2 Global Market by Application Segment Growth Chart
    • 7.2.3 Global Market by Application Segment Annual Chart
    • 7.2.4 Global Market by Application Segment Base vs. Final
    • 7.2.5 Global Market by Application Base Year
    • 7.2.6 Global Market by Application Final Year
  • 7.3 Global Market by Technology
    • 7.3.1 Global Market by Technology Table
    • 7.3.2 Global Market by Technology Segment Growth Chart
    • 7.3.3 Global Market by Technology Segment Annual Chart
    • 7.3.4 Global Market by Technology Segment Base vs. Final
    • 7.3.5 Global Market by Technology Base Year
    • 7.3.6 Global Market by Technology Final Year
  • 7.4 Global Market by Product
    • 7.4.1 Global Market by Product Table
    • 7.4.2 Global Market by Product Segment Growth Chart
    • 7.4.3 Global Market by Product Segment Annual Chart
    • 7.4.4 Global Market by Product Segment Base vs. Final
    • 7.4.5 Global Market by Product Base Year
    • 7.4.6 Global Market by Product Final Year
  • 7.5 Global Market by User
    • 7.5.1 Global Market by User Table
    • 7.5.2 Global Market by User Segment Growth Chart
    • 7.5.3 Global Market by User Segment Annual Chart
    • 7.5.4 Global Market by User Segment Base vs. Final
    • 7.5.5 Global Market by User Base Year
    • 7.5.6 Global Market by Application Final Year

8 Global Market by Application

  • 8.1 Endocrinology Applications
    • 8.1.1 Endocrinology Applications by Country Table
    • 8.1.2 Endocrinology Applications Growth Chart
  • 8.2 Immune Applications
    • 8.2.1 Immune Applications by Country Table
    • 8.2.2 Immune Applications Growth Chart
  • 8.3 Oncology Applications
    • 8.3.1 Oncology Applications by Country Table
    • 8.3.2 Oncology Applications Growth Chart
  • 8.4 Infectious Disease Applications
    • 8.4.1 Infectious Disease Applications by Country Table
    • 8.4.2 Infectious Disease Applications Growth Chart
  • 8.5 Cardiology Applications
    • 8.5.1 Cardiology Applications by Country Table
    • 8.5.2 Cardiology Applications Growth Chart
  • 8.6 Other Applications
    • 8.6.1 Other Applications by Country Table
    • 8.6.2 Other Applications Growth Chart

9 Immunoassay by Technology

  • 9.1 Enzyme
    • 9.1.1 Enzyme by Country Table
    • 9.1.2 Enzyme Growth Chart
  • 9.2 Flourescence
    • 9.2.1 Flourescence by Country Table
    • 9.2.2 Flourescence Growth Chart
  • 9.3 Chemiluminescence
    • 9.3.1 Chemiluminescence by Country Table
    • 9.3.2 Chemiluminescence Growth Chart
  • 9.4 Nucleic Acid
    • 9.4.1 Nucleic Acid by Country Table
    • 9.4.2 Nucleic Acid Growth Chart
  • 9.5 Rapid/POC
    • 9.5.1 Rapid/POC by Country Table
    • 9.5.2 Rapid/POC Growth Chart
  • 9.6 Other Technology
    • 9.6.1 Other Technology by Country Table
    • 9.6.2 Other Technology Growth Chart

10 Immunoassay by Product

  • 10.1 Instrument
    • 10.1.1 Instrument by Country Table
    • 10.1.2 Instrument Growth Chart
  • 10.2 Reagents
    • 10.2.1 Reagents by Country Table
    • 10.2.2 Reagents Growth Chart
  • 10.3 Services
    • 10.3.1 Services by Country Table
    • 10.3.2 Services Growth Chart

11 Immunoassay by User

  • 11.1 Hospital
    • 11.1.1 Hospital by Country Table
    • 11.1.2 Hospital Growth Chart
  • 11.2 Outpatient Lab
    • 11.2.1 Outpatient Lab by Country Table
    • 11.2.2 Outpatient Lab Growth Chart
  • 11.3 POC/Other
    • 11.3.1 POC/Other by Country Table
    • 11.3.2 POC/Other Growth Chart

12 Vision of the Future of Immunoassay

13 Appendices

  • 13.1 United States Medicare System: 2021 laboratory Fees Schedule

Table of Tables

  • Table 1 Market Players by Type
  • Table 2 Clinical Laboratory Departments and Segments
  • Table 3 Laboratory Management Focus - Different Approaches
  • Table 4 Key Segmentation Variables Going Forward
  • Table 5 The Different Markets for Immunoassay
  • Table 6 The Factors Driving Growth
  • Table 7 Factors Limiting Growth
  • Table 8 - Listing of Instrument Specifications
  • Table 9 The Global Immunoassay Market by Country
  • Table 10 Global Market by Application
  • Table 11 Global Market by Technology
  • Table 12 Global Market by Product
  • Table 13 Global Market by User
  • Table 14 Endocrinology Immunoassay by Country
  • Table 15 Immune Immunoassay by Country
  • Table 16 Oncology Immunoassay by Country
  • Table 17 Infectious Disease Immunoassay by Country
  • Table 18 Cardiology Immunoassay by Country
  • Table 19 Other Immunoassay by Country
  • Table 20 Enzyme Immunoassay by Country
  • Table 21 Flourescence Immunoassay by Country
  • Table 22 Chemiluminescence Immunoassay by Country
  • Table 23 Nucleic Acid Immunoassay by Country
  • Table 24 Rapid/POC Immunoassay by Country
  • Table 25 Other Technology Immunoassay by Country
  • Table 26 Instrument by Country
  • Table 27 Reagents by Country
  • Table 28 Services by Country
  • Table 29 Hospital Usrr by Country
  • Table 30 Outpatient Lab by Country
  • Table 31 POC/Other by Country
  • Table 32 2021 Clinical Lab Fee Schedule

Table of Figures

  • Figure 1 The Lab Test Pie
  • Figure 2 Immunoassay - Country Sharea
  • Figure 3 Chart of Growth by Application
  • Figure 4 Chart of Segment by Year
  • Figure 5 Chart of Base vs. Final
  • Figure 6 Chart of Base Year by Application
  • Figure 7 Chart of Final Year by Application
  • Figure 8 Chart of Growth by Technology
  • Figure 9 Chart of Technology Segment by Year
  • Figure 10 Chart of Technology Base vs. Final
  • Figure 11 Chart of Base Year by Technology
  • Figure 12 Chart of Final Year by Technology
  • Figure 13 Chart of Growth by Product
  • Figure 14 Chart of Product Segment by Year
  • Figure 15 Chart of Product Base vs. Final
  • Figure 16 Chart of Base Year by Product
  • Figure 17 Chart of Final Year by Product
  • Figure 18 Chart of Growth by User
  • Figure 19 Chart of User Segment by Year
  • Figure 20 Chart of User Base vs. Final
  • Figure 21 Chart of Base Year by User
  • Figure 22 Chart of Final Year by User
  • Figure 23 Chart - Endocrine Segment vs Total Market Growth
  • Figure 24 Chart - Immune Growth vs. Total
  • Figure 25 Chart - Oncology vs Total
  • Figure 26 Chart - Infectious Disease Immunoassay vs Total
  • Figure 27 Chart - Cardiology Immunoassay vs total
  • Figure 28 Chart - Other Immunoassay vs Total
  • Figure 29 Chart - Enzyme Segment vs Total Market Growth
  • Figure 30 Chart - Flourescence Growth vs. Total
  • Figure 31 Chart - Chemiluminescence vs Total
  • Figure 32 Chart - Nucleic Acid Immunoassay vs Total
  • Figure 33 Chart - Rapid/POC Immunoassay vs total
  • Figure 34 Chart - Other Technology Immunoassay vs Total
  • Figure 35 Chart - Instrument Segment vs Total Market Growth
  • Figure 36 Chart - Reagents Growth vs. Total
  • Figure 37 Chart - Services vs Total
  • Figure 38 Chart - Hospital Segment vs Total Market Growth
  • Figure 39 Chart - Outpatient Lab Growth vs. Total
  • Figure 40 Chart - POC/Other vs Total